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Previous infection with Epstein-Barr virus (EBV) is believed to trigger autoimmunity
and to drive autoantibody generation as occurring in patients with systemic lupus
erythematosus (SLE). Complement C1q and autoantibodies targeting it (anti-C1q) are
also considered to be involved in the pathogenesis of SLE, independently of the impact
of environmental insults. Still, the circumstances under which these autoantibodies arise
remain elusive. By studying a major antigenic site of C1q targeted by anti-C1q (A08),
we aimed to determine environmental factors and possible mechanisms leading to the
development of anti-C1q. First, we determined antigenic residues of A08 that were
critical for the binding of anti-C1q; importantly, we found the binding to depend on
amino-acid-identity. Anti-C1q of SLE patients targeting these critical antigenic residues
specifically cross-reacted with the EBV-related EBNA-1 (Epstein-Barr virus nuclear
antigen 1)-derived peptide EBNA348. In a cohort of 180 SLE patients we confirmed
that patients that were seropositive for EBV and recognized the EBNA348 peptide had
increased levels of anti-A08 and anti-C1q, respectively. The correlation of anti-EBNA348
with anti-A08 levels was stronger in SLE patients than in matched healthy controls.
Finally, EBNA348 peptide-immunization of C1q−/−mice induced the generation of cross-
reactive antibodies which recognized both the A08 epitope of C1q and intact C1q. These
findings suggest that anti-C1q in SLE patients could be induced by an EBV-derived
epitope through molecular mimicry, thereby further supporting the pathogenic role of
EBV in the development of SLE. Considering the role of C1q and anti-C1q, modifying the
anti-EBV response might be a promising strategy to improve the course of the disease.
Keywords: systemic lupus erythematosus, anti-C1q antibody, A08 epitope, Epstein-Barr virus, EBNA-1, C1q
deficient mice, autoimmunity, molecular mimicry
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INTRODUCTION
Systemic Lupus Erythematosus (SLE) is an autoimmune disease
characterized by the occurrence of autoantibodies, resulting in
a broad spectrum of immunological and clinical manifestations.
Among the severe manifestations of SLE, renal involvement is
the most frequent and, in its most aggressive forms, can lead to
renal failure.
Besides the heterogeneous clinical presentation, the
pathogenesis of SLE is most likely due to a combination of
genetic predisposition with hormonal and environmental
factors, such as ultraviolet light, chemicals, medication, and
parasitic, bacterial or viral infections. The hypothesis that
viral infections might initiate autoimmunity is supported by
clear epidemiological, clinical and experimental data. Viruses
such as Cytomegalovirus, Parvovirus B19 and Epstein-Barr
virus (EBV) have been well described to be environmental
triggers of SLE (1–4). EBV infection attracted specific attention
because SLE patients seem to form aberrant antibodies, with the
potential to cross-react with autoantigens by means of molecular
mimicry. Moreover, experimental immunization of animals with
EBV-derived peptides has been shown to induce typical SLE
autoantibodies (5–8).
In humans, the characteristic autoantibodies can appear many
years before the first clinical manifestation of the disease (5,
9). Among these autoantibodies, some have been considered
to be pathogenic based on their close association with disease
activity and their target being involved in the pathogenesis of
SLE. In this sense, autoantibodies against C1q (anti-C1q), the
starter molecule of the classical pathway of complement, are
of specific interest. On the one hand, anti-C1q correlate with
overall disease activity (10) and the occurrence of severe lupus
nephritis (11–13), making them an important diagnostic marker.
On the other hand, C1q is deposited in inflamed tissues and
associated with complement activation as well as the deposition
of immune complexes (14). Thus, anti-C1q have the potential
to accelerate the course of disease (15, 16). One important
rationale for the role of C1q and anti-C1q in SLE is based
on the so-called “waste disposal” hypothesis. This assumes that
SLE is driven by a defective clearance of dying cells that can
become antigenic and drive autoimmunity. In fact, C1q has been
described to accelerate the clearance of self-antigens generated
during apoptosis, and macrophages from C1q-deficient mice and
humans show a defective clearance of apoptotic cells in vitro
(17, 18). In SLE patients, this physiological function of C1q is
likely to be altered by the binding of anti-C1q. Anti-C1q most
frequently target a cryptic epitope on the collagen-like region of
C1q. In a previous study, we identified a major linear epitope of
C1q located on the collagen-like stalk region of C1q, the so-called
A08. Autoantibodies against this single peptide epitope (anti-A08
IgG) have also been found to correlate with SLE disease activity
and lupus nephritis (19, 20).
The aim of our study was to characterize the antigenic
site A08 of C1q with the goal to determine a possible
connection to environmental antigens, which could trigger
the development of anti-C1q. Revealing mechanisms leading
to the generation of anti-C1q as a consequence of exposure
to specific pathogens would allow specific and preventive
immunotherapeutic approaches with the aim to reduce the
incidence and severity of systemic autoimmunity.
MATERIALS AND METHODS
Serum/Clinical Serum Samples
Sera/plasma from patients included in the Swiss Systemic
Lupus Erythematosus Cohort Study (SSCS) were selected based
on the availability of biomaterial and complete SLE disease
activity measures at the time of inclusion and sampling. SLE
patients (n = 180) fulfilled at least 4/11 classification criteria
of the American College of Rheumatology (ACR). On average,
patients had a median age of 43 years (range 16–84, 86.2%
females), disease duration of 10.5 years (since diagnosis) and a
median SLEDAI score of 4 at the time-point of blood sampling
(see Supplementary Table 1). Additionally, sera from selected
SLE patients (n = 17) (introduced in a previous study (19)
and with known anti-C1q and anti-A08 IgG levels covering
a broad range of titers) were also included in the study
(Supplementary Table 2). Normal human sera (NHS) from 189
age- and sex-matched blood donors (median age 49 years, range
19–81, 85.6% females) recruited during routine donations at the
Blood Transfusion Center Basel (Blood Transfusion Center Basel,
Swiss Red Cross, Basel, Switzerland) were used as controls. All
samples were anonymized.
We defined SLE patients with a Physician’s Global Assessment
(PGA) of 1 or higher as having active disease. Additionally,
active patients included in Supplementary Table 1 and in the
correlation analysis were also VCA and EBNA-1 positive.
SSCS was approved by the Ethical Committee of the Canton
Basel, Switzerland (Ref No EK 262/06) and fulfilled the guidelines
of the most recent Declaration of Helsinki. Patients gave written
informed consent for the study participation.
Mice
Six to nine week-old C57BL/6N and C1qa−/− female mice (21)
with a body weight of approximately 19 g, were obtained from
the animal facility of the Department of Biomedicine, where they
were maintained under pathogen-free conditions. The C1qa−/−
mice were on a C57BL/6N genetic background backcrossed
for at least 10 generations. Mice were distributed randomly to
the different groups. Immunizations were performed (s.c.) on
mice narcotized with isoflurane. This study was carried out
in accordance with the recommendations of the Swiss welfare
legislation (consisting of Animal Welfare Ordinance, Animal
Welfare Act and the Animal Experimentation Ordinance) The
protocol was approved by the Cantonal Commission for Animal
Experiments, and the Federal Food Safety and Veterinary Office
(2633/23801), and performed by authorized staff.
Peptides
N-terminally biotinylated and non-biotinylated peptides with
>95% purity were synthesized by GenScript (USA) and peptides
& elephants GmbH (Germany). The A08 peptide (sequence):
GRPGRRGRPGLKG is derived from the A chain of C1q. A08
peptide variants used for the AAs (amino acids) exchange
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experiments are summarized in Figure 1A. The AAs sequence of
microorganisms-derived peptides and peptides derived from the
human proteome having a sequence identity to the core of A08,
as well as a scrambled version of the A08 peptide are summarized
in Supplementary Table 3.
Sequence Alignment
The vertebrate C1q sequences were extracted from the vertebrate
reference sequence database of NCBI and a semi global MALT
alignment was performed with a 25 AAs long query sequence
containing the A08 sequence. Significance of alignment was
judged by the e value. The species selected from the generated
file are summarized in Supplementary Table 4.
Protein BLAST with the GRRGR core sequence was carried
out on the human proteome (Homo sapiens, taxid 9606) of the
UniProtKB/Swissprot sequence database. For this we looked at
the first 50 hits (all had a score of 18.5, with an e value of 17) and
selected proteins based on the following keywords listed in the
protein database of NCBI: secreted, cell death-related, immunity-
related, collagen. Microorganisms-related proteins containing
the core sequence were retrieved in a similar way. The organisms’
dataset was narrowed down to certain pathogens based on
their association with the occurrence of SLE and/or assumed
causal relationship (1, 22). A list of selected peptide sequences
is summarized in Supplementary Table 3.
ELISA for Assessment of Antibodies in
Human and Mouse Serum
EBV Seroprevalence and Anti-C1q in Clinical
Samples
The seroprevalence of EBV was determined by serum ELISAs
for anti-VCA IgG (Meridian Bioscience Inc.) and anti-EBNA-
1 (Epstein-Barr virus nuclear antigen 1) IgG (Abnova). We
determined the anti-VCA levels in a semi-quantitative way,
using kit calibrators that allow the unit value determination
of each sample. The serum was diluted 20-times and the
secondary detection antibody was a goat-anti-human IgG-
HRP (γ-chain specific). For the anti-EBNA-1 assay the
recombinant immunodominant epitopes of the EBNA-1 were
incubated with 100-times diluted serum samples. The antigen-
antibody complexes were then recognized by a horseradish
peroxidase labeled anti-human IgG-HRP (γ-chain specific)
and the enzymatic reaction was visualized with TMB as a
chromogenic substrate. Both commercially available kits provide
standardized solutions to be included on each assay plate to
calculate an individual standard curve. This standard curve
covers the linear part of the curve and includes a negative control.
The AUs were directly derived from the standard curve without
modifying calculations. The assay for anti-EBNA-1 included
the following controls: negative, 20, 45, 90, and 500AU. The
manufacturers’ protocol gives 12AU as cut off for positivity. The
assay for anti-VCA included the following controls: negative,
12, 396, 725AU and positive. The manufacturers’ protocol
gives 150AU as cut off for positivity. When analyzing the
associations between anti-EBNA-1 IgG and anti-EBNA348 IgG,
it is important to note that the anti-EBNA-1 IgG kit might not
contain the sequence of the EBNA348 peptide.
Anti-C1q IgG levels were determined using a commercially
available assay (Bühlmann Laboratories, Schönenbuch,
Switzerland) following the manufacturer’s instructions.
Standardization of the anti-C1q ELISA is based on defined
calibrators which are calibrated against an internal reference
sample. The reference sample is derived from a plasmapheresis
of a highly positive and clinically well-defined patient. The
cut-off is set at 15AU by the manufacturer.
As control autoantibodies, anti-ß2GPI levels were measured
according to a published protocol (23).
All ELISAs were performed in one step with each sample
in duplicates.
Peptide ELISA for Clinical Serum Samples
Polystyrene plates (MaxiSorp, Nunc) were coated with 350
ng/well NeutrAvidine (Thermo Fisher) in 0.2M bicarbonate
buffer (pH 9.6) for 1 h at 37◦C. A 2 h incubation with 500 ng/well-
biotinylated peptides followed. Sera [diluted 1: 500 in 0.05%
Tween20, 0.4M NaCl-PBS (w/v)] were added to the plate for 1 h.
Bound antibodies were detected by a 10,000-fold diluted,
alkaline-phosphatase (AP) labeled goat anti-human IgG-Fc
gamma chain specific secondary (#109-055-008 Jackson Immuno
Research). OD was read (405 nm) and analyzed using a Synergy
H1 Hybrid ELISA reader and Gen5 Analysis Program (BioTek).
All incubation steps were performed at 27◦C if not stated
differently, and were followed by a washing step using 0.05%
Tween20-PBS (w/v). For data analysis results were normalized:
all measured values were expressed in units relative to the
OD values of the reference SLE serum. The reference serum
had high level anti-EBNA348 IgG and high level anti-A08
IgG. The corresponding OD values on each plate were set to
100AU. The reference serum was included on each plate/in each
experiment. Samples were tested in duplicates. A conservative
cut-off, considering the non-normal distribution of the values,
was defined by the median value (AU) plus 3 median absolute
deviations of the EBV seropositive normal human donors:
105AU for the anti-EBNA348 IgG- and 82AU for the anti-A08
IgG assay.
The peptide ELISAs with human serum were done twice with
each sample in duplicates. The results shown are originating from
one experiment though with the other one confirming the results.
Peptide, Anti-C1q and ANA ELISA for Mouse Sera
The presence of anti-peptide and anti- human C1q IgG in
mouse serum was confirmed by an assay similar to the one
described above. Polystyrene plates (MaxiSorp, Nunc) were
coated with 500 ng/well NeutrAvidine or 350 ng/well-purified
human C1q (Complement Technology) protein, respectively,
in 0.2M bicarbonate buffer (pH 9.6), o/n at 4◦C. A 2 h
incubation with 500 ng/well-biotinylated peptides followed on
the NeutrAvidine coated plates. The mouse sera (diluted 1:500
in 0.05% Tween20-PBS (w/v) or 1:10 in 0.5M NaCl in 0.05%
Tween20-PBS) were incubated for 1.5 and 1 h, for the peptide
and the protein assays, respectively. Point five molar NaCl-
Tween20-PBS (=high-salt) buffer was used to prevent immune
complex binding to intact C1q. Bound IgG was detected by
a 20,000-fold diluted horseradish peroxidase (HRP)-conjugated
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FIGURE 1 | Identifying the binding core in the C1q-derived epitope A08. (A) Variations of the A08 peptide with 1, 2, or 3 AAs substitutions: Arg (R) was exchanged for
Ala (A) and Lys (K) in order to alter the net charge of the peptide (at neutral pH) or to modify its sequence. (B) Serum from the reference SLE patient shows a specific
binding pattern to the A08 peptide variations. Binding is expressed as percentage relative to the 100% binding to the original A08. (C) Serum from SLE patients with
anti-A08 IgG (n = 13), with low-to no levels of anti-A08 IgG (n = 3) and from healthy donors (NHS) (n = 5) were tested on a selection of A08 peptide variations. Bar
graphs show median with IQR. *p ≤ 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Ab, antibody.
Fcγ-specific rabbit anti-mouse secondary (#SAB3701037, Sigma)
and TMB substrate (BD Bioscience). For the protein assay the
secondary too was diluted in salt-containing buffer. OD was
read (450 nm) and analyzed as described above. Incubation steps,
if not otherwise mentioned, were at room temperature, and
were followed by washing with 0.05% Tween20-PBS. For data
analysis results were normalized. The standard positive sample
(from an MRL-lpr mouse with high anti-EBNA348-, anti-A08-,
and anti-C1q IgG levels) was included in each experiment/plate.
Additionally, for the peptide ELISAs, the signal obtained from
incubating sera (human or murine) with NeutrAvidine was
considered background, and was subtracted from the specific
signal. Samples were tested in duplicate. The cut-off for the
mouse anti-human C1q ELISA was set at 0.061 OD by calculating
the median OD value at 450 nm + 3 median absolute deviations
of the OD values of adjuvant-injected control mice. Anti-
C1q ELISAs were repeated twice, each time with samples in
duplicates; data shown are from a single experiment. For the
data shown, anti-A08 and anti-EBNA348 assays were performed
once, with samples in duplicates. Anti-C1q measurements were
Frontiers in Immunology | www.frontiersin.org 4 November 2019 | Volume 10 | Article 2619
Csorba et al. Viral Peptide Mimic in C1q Autoimmunity
performed twice, with duplicates for each sample; data included
originated from one experiment.
Serum anti-nuclear antibodies (ANA) were determined
by a commercially available mouse ANA ELISA Kit (Alpha
Diagnostic, San Antonio, TX), according to the manufacturer’s
protocol. Plates precoated with purified nuclear antigens were
incubated with mouse sera [1:500 in 0.05% Tween20-PBS
(w/v)] for 1 h. Bound antibodies were detected with the anti-
mouse IgG + IgA + IgM (H + L) HRP conjugate and the
enzymatic reaction was visualized by adding TMB substrate.
The reaction was stopped with 0.25M sulphuric acid and the
absorbance measured at 450 nm using a micro plate reader
(Bio-Tek). Test sample concentrations were interpolated using
a four-parameter logistic calibration curve to the standards
provided by the manufacturer (50, 200, 500, and 1,000 U/mL).
The experiment was performed once, with duplicates for
each sample.
Inhibition Assay
Inhibition of serum IgG binding to C1q was performed
as described above, except that patient sera were diluted
300-times in 0.4M NaCl-PBS buffer and pre-incubated with
soluble EBNA-1 for 2.5 h at room temperature on a shaking
platform (300 rpm/min). A protein amount was used to
reach a molar excess of ∼3-fold the average amount of
IgG present in NHS (12 mg/ml IgG). Prior to adding the
pre-incubated and diluted patient sera to the C1q coated
plate we added NaCl crystals to each tube in order to
obtain a 1M NaCl-PBS (=high salt) buffer, which is essential
to prevent non-specific immune complex binding to intact
human C1q (24). The sera were not diluted further. After 1 h
incubation at room temperature on a shaker, bound IgG was
detected by a 5,000-times diluted alkaline phosphatase-(AP)-
conjugated rabbit-anti-human IgG (Promega) in 0.5M NaCl-
0.05% Tween20-PBS buffer (1 h, shaking). Subsequently, color
development with AP substrate (Sigma-Aldrich) and reading of
OD 405 nm at defined timepoints (12± 2min after initiating the
enzymatic reaction).
For each patient serum at least two conditions were pre-
incubated in each experiment: the one that contained EBNA-1
in excess (different amounts) and the one that had no EBNA-
1, but only the 0.4M NaCl-PBS buffer. Samples were run in
duplicates. Individual experiments were run 2 or 3 times, data
shown are pooled.
Prior to use, the commercially available EBNA-1 protein
(Advanced Biotechnologies 10-523-001) was subjected to an
∼50 h dialysis, at 4◦C. This step was necessary because the
protein was initially solubilized in 6M urea (buffer which
is incompatible with most of the assays). We gradually
removed the urea while increasing the NaCl concentration
(up to 0.4 M-NaCl in PBS), a condition that according
to the manufacturer allows the protein to slowly re-fold.
After dialysis we centrifuged the soluble EBNA-1-0.4M
NaCl-PBS solution to remove possibly precipitated protein:
40min, 4◦C, at 10.000 × g and used it immediately for
downstream analysis.
Immunization of Mice With the EBNA348
(EBNA-1-Derived EBNA-1348) Peptide
In order to induce an EBNA-1-derived peptide-specific
autoimmune response C57BL/6N (n = 10/group) and C1qa−/−
mice (n = 13/group) were immunized s.c. at the tail base
with 100 µg of EBNA348 peptide: GSGGRRGRGRERARGGS
emulsified in CFA (Invivogen). Booster injections followed
after 2, 4, and 8 weeks with peptide in IFA (Invivogen). Mice
of the control group (n = 5 C57BL/6N, n = 13 C1qa−/−) were
immunized with PBS emulsified in CFA and IFA, respectively.
CFA immunized mice were monitored closely and the general
health condition of the animals was evaluated thrice a week
throughout the experiment. Mice were weighed and bled
before immunization and boosters, and 10 days after the 2nd
and 3rd boost, for a period of 12 weeks. Sera were tested for
autoantibody titers and cross-reacting antibodies. One C1qa−/−
mouse (control group) was excluded early in the experiment
due to its considerably lower weight, and a C57BL/6N mouse
(peptide-immunized group) died during the experiment,
thus results and figures are reporting 12 C1qa−/− adjuvant
control mice and 9 C57BL/6N peptide immunized mice, if not
mentioned otherwise. Immunization experiments were repeated
twice in each strain to confirm the results; data shown are from
single experiments.
The rationale behind our choice of the C1qa−/− mouse strain
was that we wished to reconstitute the cross-reactivity in a system
where we have no intrinsic target nor preformed antibodies
against the target (A08/C1q) interfering with the results as
observed in lupus-prone mice (25, 26).
Statistics
Non-parametric testing between two or more groups
was performed by two-tailed Mann–Whitney-U or
Kruskal-Wallis test, correlations were estimated by
Spearman’s rho, and contingency tables were analyzed
by Fisher’s exact test using Prism 7 software (GraphPad
Software, La Jolla California USA, www.graphpad.com).
Correction for multiple testing was done with the
Bonferroni method. Statistical significance was considered
with p ≤ 0.05; ∗p ≤ 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,
∗∗∗∗p < 0.0001.
RESULTS
Binding of Anti-C1q to the Core of A08 Is
Amino Acid Identity-Dependent
Previously, we described a major linear epitope of complement
C1q targeted by anti-C1q of SLE patients, the A08 peptide.
Antibodies binding to it were validated as a biomarker for
active lupus nephritis (19, 20). We now characterized the
A08 epitope and identified, by interspecies sequence alignment,
the arginine in position 6 (Arg6) as unique to human C1q
(Supplementary Table 4). We also tested whether the Arg and
other amino acids (AAs) are essential for anti-C1q binding,
by generating A08 versions (Figure 1A) with modified net
charges [Arg to alanine (Ala)] or/and sequence [Arg to
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Lysine (Lys), glycine (Gly) to Ala]. Initially, we found that
the Arg5, 6, 8, and the Gly7 are required for full anti-
C1q binding (Figure 1B) thus forming a critical residue motif
for antigenicity: RRGR. The extended screening, with higher
numbers of sera from SLE patients (Supplementary Table 2
and Figure 1C) and normal donors confirmed the importance
of the central contiguous RRGR AAs for anti-C1q binding.
Regardless of single Arg residues being replaced by Ala or
Lys, the signal, expressed as binding percentage relative to
A08, dropped by 70–85%, except for A08K5 (Figure 1B).
Furthermore, double and/or triple substitutions of the Arg
led to progressive loss of antibody binding (Figures 1B,C).
Additionally, exchanging arginines for neutral residues (Ala)
abrogated the binding signal. However, the reconstruction
of the peptide with a similarly charged AA (Lys), did
not recover the signal (Figure 1C). Further on, sera of
normal donors and of SLE patients with low-to no anti-A08
IgG recognized A08 and its variations to the same extent,
but significantly less than the SLE patients with anti-A08
IgG (Figure 1C).
Anti-C1q Directed Against the A08 Core
Sequence Recognize the EBNA-1-Derived
EBNA348 Peptide
While the full A08 peptide sequence is unique to human
C1q, its core RRGR sequence occurs in other proteins too.
Next, we aligned the A08 core sequence to the human
proteome and to a microorganism-derived protein dataset and
screened selected peptides (Supplementary Table 3). Regarding
microorganism-derived peptides, it was striking that anti-C1q
of SLE patients also recognized the EBNA-1-derived peptide
“EBNA348,” i.e., a 17 AAs long peptide starting at position 348
TABLE 1 | Statistical characteristics of EBV seroprevalence.
Clinical test SLE
(n = 180)
NHS
(n = 189)
OR (95% CI) P-value
EBV seroprevalence 98.9% 94.7% 4.97
(1.07–23.02)
0.036
VCA seropositivity 98.3% 91.5% 5.45
(1.56–19.07)
0.0037
EBNA-1 seropositivity 91.7% 90.5% 1.16
(0.43–3.17)
0.7
OR, odds ratio; seroprevalence includes VCA and/or EBNA-1 seropositivity.
of EBNA-1 (Figure 2A). The binding to A08 and EBNA348
was equally strong, while the level of binding to all other
pathogen-derived peptides was significantly lower (p = 0.0001,
for all differences in binding between A08 and the other
pathogen-derived peptides), suggesting a specific binding of
SLE sera to EBNA-1 of EBV. Additionally, we analyzed human
protein-derived peptides for which we could not observe
an overall, specific and strong signal, such as the one to
EBNA348. Binding to A08 was significantly stronger when
compared to other peptides (Bonferroni corrected significance:
ScrA08 p = 0.0001, AChE Q p = 0.015, Col XI-a-2 p
= 0.0001, Semaphorin p = 0.0001, PACS-2 p = 0.021,
Col V-a-1 p = 0.0014), with the exception of cell death
regulator Aven (AVEN). However, in this non-exclusive set
of peptides only AVEN was recognized not only by SLE
patients’ but also by normal human donors’ sera (Figure 2B),
and this binding did not differ significantly (Bonferroni
corrected p = 0.19), suggesting that the reaction to AVEN is
not SLE-specific.
FIGURE 2 | Binding to different microorganism-derived peptides (A) and human protein-derived peptides (B) containing the core AAs sequence of A08 was
measured in SLE patients (n = 14) and healthy donors (NHS) (n = 8). Bar graphs show median with IQR. **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.
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FIGURE 3 | Serum levels of anti-EBNA-1 IgG, anti-EBNA348 IgG and anti-A08 IgG in SLE patients and normal human donors. (A) Anti-EBNA-1 IgG was measured in
SLE patients (n = 180, •) and normal human controls (n = 189, ). Dashed line indicates the kit-defined cut-off (12AU). **p = 0.0084. Anti-EBNA348 IgG (B) and
anti-A08 IgG (C) levels were analyzed in EBV seropositive sera further grouped based on their anti-EBNA-1 status. N = 165, •/ n = 13, , are anti-EBNA-1 positive
and negative SLE patients, respectively. N = 171, / n = 8, , are anti-EBNA-1 positive and negative NHS, respectively. *p ≤ 0.05, **p = 0.0019 for panel A and
**p = 0.0094 for panel B, ****p < 0.0001. Dot plots show median with IQR.
EBV Seropositive SLE Patients
Recognizing the EBNA-1-Derived EBNA348
Peptide Have Higher Levels of Anti-A08
IgG and Anti-C1q
As SLE patients might form an aberrant antibody reaction
to the EBNA-1-derived peptide EBNA348, we next explored
the association of antibodies against EBV with antibodies
against intact C1q and the C1q-derived epitope A08. For
this, we analyzed the overall seropositivity for EBV based
on antibody titers against common EBV antigens in a large
number of SLE patients being included in the Swiss SLE Cohort
Study (SSCS).
Overall EBV seropositivity, as defined by positivity for
either anti-VCA IgG and/or anti-EBNA-1 IgG, was higher
in SLE patients than in healthy controls (Table 1). Also,
levels of anti-EBNA-1 IgG were higher in SLE patients
(Figure 3A), which did not correlate with levels of total
IgG (r = 0.1178).
Secondly, SLE patients with a positive anti-EBNA-1 IgG
response also form anti-EBNA348 IgG antibodies with anti-
EBNA348 IgG levels being significantly higher in anti-EBNA-1
IgG positive SLE patients than in normal human controls (p <
0.0001) (Figure 3B).
We then investigated, whether seropositivity for EBV is also
associated with antibodies against A08 of C1q and intact C1q,
respectively, and whether anti-EBNA348 IgG correlate with these
autoantibodies. Indeed, as shown in Figure 3C anti-A08s IgG
levels were significantly higher in anti-EBNA-1 IgG positive
SLE patients than in normal human controls (p < 0.0001).
Additionally, in an inhibition assay with recombinant EBNA-
1, we observed a median inhibition of anti-C1q levels by
9% (range 0–40%) in sera of SLE patients (n = 4 patients,
n = 3 experiments), this being in the range of the anti-
A08 specific fraction of total anti-C1q antibodies (19) (see
Supplementary Figure 3).
Furthermore, the correlation of anti-EBNA348 IgG levels with
levels of anti-A08 IgG was stronger in unselected SLE patients
(r = 0.61, Figure 4A) than in healthy controls (r = 0.5) and
was most pronounced in SLE patients with active disease (r
= 0.66, Figure 4B). Double-positivity (for anti-EBNA348 IgG
and anti-A08 IgG) was found only once among healthy donors,
while normal human donors more frequently showed high anti-
EBNA348 IgG levels without corresponding anti-A08 IgG levels
(Supplementary Table 5).
Last, anti-C1q levels were significantly higher in
anti-EBNA348 IgG positive SLE patients (p = 0.019)
(Supplementary Figure 1A), and vice versa, SLE patients
with positive anti-C1q had higher levels of anti-EBNA348 IgG, p
= 0.006. This difference remains significant even after exclusion
of data points with anti-C1q levels below 15AU, i.e., exclusion
of anti-C1q negative individuals (Supplementary Figure 1B).
In comparison, levels of anti- ß2GPI IgG antibodies were not
found to be associated with positivity for anti-EBNA348 IgG
(Supplementary Figure 2).
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FIGURE 4 | Correlation of anti-A08 IgG and anti-EBNA348 IgG serum levels in
(A) SLE patients (CI 0.49–0.70, n = 165) and in (B) SLE patients with active
disease (CI 0.51–0.78, n = 76). The dashed lines indicate cut-offs for
anti-EBNA348 IgG (105AU) and anti-A08 IgG (82AU) serum levels.
EBNA348 Peptide Can Induce a Humoral
Immune Response to C1q in vivo
In order to confirm our patient data-based hypothesis that an
EBV-derived antigenic site can induce an immune response
against complement C1q, C1qa-deficient mice (n = 13) were
immunized with the EBNA348 peptide. Of the immunized mice,
10 developed specific anti-EBNA348 antibodies (Figure 5A) and
also developed an immune response against the C1q-derived A08
peptide (Figure 5B). No antibodies, either against EBNA348, or
A08 could be detected in the adjuvant control group (n = 12).
Of note, we also immunized wild-type C57BL/6N mice with the
EBNA348 peptide (n= 10). Of the 9 mice that could be analyzed,
8 developed a peptide-specific immune response (Figure 5C),
but antibodies against the A08 peptide were not detected
(Figure 5D). As in C1q-deficient mice, no anti-EBNA348- or
anti-A08 IgG were observed in the adjuvant control group (n
= 5). When comparing the EBNA348-specific immune response
levels between wild-type and C1q−/− mice we found a significant
difference right after the second boost (B2) and at the final
bleeding (FB). In case of the anti-A08 IgG levels, the difference
between the two strains becomes apparent at the final bleeding
(see Supplementary Table 6).
We also measured anti-C1q IgG in the sera of C1q−/−
and wild-type mice, in immunized and control serum samples.
Among the EBNA348-immunized mice showing continuous and
increasing levels of anti-A08 IgG (n = 6), 3 had antibodies
binding to intact human C1q (Figure 5E). On the other hand,
none of the C57BL/6N immunized mice (n = 8) had anti-C1q
IgG (Figure 5F). Differences in positivity for anti-C1q as well
as in levels of anti-C1q were significant in immunized C1q−/−
mice (two tailed Mann-Whitney, p= 0.01, and Fisher’s exact test,
p = 0.024), whereas there was no such difference in the wild-
type mice (two tailedMann-Whitney, p= 0.43, and Fisher’s exact
test, p > 0.99).
Of note, we also measured ANA in the sera of C1q−/−
and wild-type mice (Figures 5G,H) and observed no difference
between the peptide immunized and control mice (two tailed
Mann-Whitney p= 0.41 and p= 0.52, respectively).
DISCUSSION
Although the waste disposal hypothesis provides a fundamental
explanation for the development of autoantibodies, additional
environmental factors, such as infectious agents, seem to be
required to drive the autoimmune process.
In fact, in EBV infected SLE patients an altered virus-specific
immune response against EBNA-1 epitopes can lead to antibodies
cross-reacting with common lupus antigens. However, the cross-
reacting antibodies described thus far neither seem to clearly
correlate with disease activity nor are they commonly considered
pathogenic. Our study suggests that anti-C1q in SLE patients
can be induced by an EBV-derived peptide epitope through
molecular mimicry. This observation is of importance since
cross-reactivity as observed here seems to be based on sequence
identity, and the target (C1q), as well as autoantibodies against
it (i.e., anti-C1q) have been implicated in the pathogenesis of
SLE (27).
Multiple lines of evidence support the involvement of C1q in
SLE development. Loss of function mutations in C1q, although
a rare event, are the strongest known susceptibility factor
for the development of SLE (28). Additionally, active kidney
inflammation (lupus nephritis) in C1q-sufficient SLE patients is
not only associated with low levels of C1q but also with high levels
of anti-C1q (13, 29). It is most likely that anti-C1q are altering
the course of disease, especially since they have been shown
to be deposited in glomeruli of patients with lupus nephritis
(30), and seem to be a prerequisite for the occurrence of severe
lupus nephritis (29). Concerning the binding site of anti-C1q, a
linear antigenic region within the A chain of the C1q molecule
(A08) was described as a major target in SLE patients (19).
Now we describe that antibodies specific for the EBNA-1-derived
EBNA348 peptide cross-react with A08 of C1q, which links a
known risk factor for SLE with a pathogenic autoantibody in
lupus nephritis.
Although we and others observed no significant difference in
EBNA-1 IgG seroprevalence between SLE patients and controls
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FIGURE 5 | Specific humoral immune response and cross-reactivity in EBNA348 peptide-immunized C57BL/6N and C1qa−/− mice. (A) In C1qa−/− mice the
EBNA348 peptide-specific immune response is associated with (B) measurable levels of cross-reacting anti-A08 IgG, n = 10. Immunized wild-type mice (C57BL/6N),
have a specific anti- EBNA348 immune reaction (C), but no anti-A08 IgG were detected (D). (E) Levels of high-affinity anti-C1q antibodies in the sera (FB) of
(Continued)
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FIGURE 5 | C1q−/−mice, positive for anti-EBNA348 IgG and anti-A08 IgG, n = 6, p = 0.01, and in the sera (FB) of C57BL/6N mice, n = 8 (F). Animals of the control
groups (n = 12 for C1q−/− and n = 5 forC57BL/6N) had no IgG against any of the measured peptides or C1q. (G,H) Serum ANA levels in the sera (FB) of C1q−/−
and wild-type mice respectively, showed no significant difference between the EBNA348-immunized and the control groups. Data were plotted as median with IQR.
PI, pre-immune; B1, 1st boost; B2, 2nd boost; B3, 3rd boost; FB, final bleed.
(31), in SLE patients faulty and/or insufficient immune and
tolerance mechanisms contribute to an aberrant anti-EBNA-1
immunity (7, 32, 33). This, on the one hand results in antibodies
targetingmore and different epitopes as compared to anti-EBNA-
1 positive normal controls, and on the other hand can promote
cross-reactive antigenic regions (32, 33).
In EBV carriers who do not suffer from SLE, the major
immunogenic domain of EBNA-1 appears to be the Gly-
Ala repeat region, while ligand-binding domains of EBNA-1
tend to be non-immunogenic (34). In contrast, antibodies in
pediatric SLE patients preferentially target the ligand-binding
N- and C-terminal parts of EBNA-1 (33). Our findings are
in line with the observation, that a substantial fraction of the
SLE patients (28.5%) had antibodies targeting the EBNA-1-
derived region EBNA348, while these antibodies were found
in <5% of the matched controls. This peptide is part of
the C-terminal Gly-Arg repeat region of EBNA-1, which
is functionally important for its interaction with the host
chromosome (35, 36).
Previous studies have reported several different regions of
EBNA-1 being recognized by antibodies specific for host proteins
such as splicesomal ribonucleoproteins SmB/B’, SmD, and Ro
(7, 8, 33, 37, 38). James et al. were the first to show that a
proline rich region of Sm B/B’ antigen is very similar to a
stretch of the non-structured C- terminal part of the EBNA-1
protein (AAs 397-404), and that SLE patients, but not healthy
controls, have antibodies targeting this epitope (37). Anti-Sm
antibodies have no direct pathogenic role or association with
disease activity. However, anti-Ro antibodies are considered to
be the strongest risk factor for neonatal lupus (39) and are an
early marker of developing lupus, but they do not correlate with
disease activity. Most importantly, anti-Ro antibodies specifically
bind a peptide-defined region in the unstructured N-terminus
of the EBNA-1 protein (AAs 58-72) (6). In this particular case,
it is noteworthy that there is no sequence identity between the
two epitopes.
In our study, we found a sequence identity of 5 consecutive
AAs, namely GRRGR, between the EBNA-1-derived EBNA348
and the C1q-derived A08 stretch. The core sequence responsible
for antibody binding is the RRGR. Although highly charged, it
is important to mention that ionic interactions alone are not
sufficient for antibody binding, as demonstrated by substitution
peptide screening and an alanine scan of the A08 peptide.
Nevertheless, given the length and the lack of uniqueness of
the core amino acid sequence it is not inconceivable that
anti-C1q/A08 can recognize other autoantigens carrying it, as
suggested by the cross-reaction with the (intracellular) cell
death regulator Aven (AVEN). However, sera of normal blood
donors were found to also have relevant reactivity against
the AVEN-derived peptide suggesting that this binding is not
SLE-specific. In fact, little is known about the function of AVEN.
The molecule is mainly associated with cancers, either as an
anti-apoptotic molecule functioning as an oncoprotein (40) or
as a predictive biomarker (41). Although the focus of our
present study was on cross-reactivity with infectious agents and
not on intrinsic proteins, we think that this finding warrants
further investigation.
Furthermore, the binding of anti-A08 IgG was found
to not only depend on the core sequence identity
but also on the flanking sequences. Control peptides
derived from pathogens or human molecules, with
the same core region as A08, were not recognized.
This might be due to charge distribution, hydrophobic
residue distribution, a combination of these and /or
other factors that might affect the correct epitope
conformation (42–44).
In the observational part of our study one major finding
was that EBNA-1 seropositive SLE patients having significantly
higher anti-EBNA348 IgG levels, also had significantly higher
levels of anti-A08 IgG. This finding strongly supports our data
and is even more striking when considering the fact that the
few normal controls having antibodies against EBNA348 did
not cross-react with A08. This observation is well in line with
the study by Marchini et al. (45) showing that anti-EBNA-1
antibodies only cross-react with Sm epitope in SLE patients but
not in healthy controls. However, in SLE patients no clear link
between anti-EBNA-1 IgG and anti-C1q could be determined.
This lack of association is most likely due to different kinetics
of the antibodies. While anti-EBNA-1 IgG levels seem to be
more stable over time (46), anti-C1q titers strongly depend on
disease activity at the time of blood sampling (47) and can even
become negative in patients with inactive disease. Accordingly,
we found the strongest correlation between anti-EBNA348 IgG
and anti-A08 IgG in patients with active disease as determined by
the Physician’s Global Assessment. However, to unmask genuine
cross-reactivity between anti-EBNA348 IgG and anti-A08 IgG
in patients, one would have to measure antibody levels at an
early stage of the disease. This perspective is based on the
hypothesis that in the initial phase of the EBNA-1 immune
response antibodies against EBNA348, that directly cross-react
with A08 (based on sequence identity), are also present. However,
anti-C1q are not only consisting of antibodies targeting A08,
but are known to be polyclonal and recognize a number of
different epitopes, among which A08 is still an important one
but by far not the only one. A well-conceivable explanation
of this phenomenon is epitope spreading eventually leading to
the secondary appearance of new anti-C1q that are not cross-
reacting with EBNA-1 any more but which are anti-C1q specific.
Thus, cross-reacting anti-EBNA348/anti-A08/anti-C1q are likely
to be an early event in the course of the disease. On the level
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of a classical patient with systemic lupus erythematosus having
advanced disease and being years after the primary infection
with EBV we would expect that the majority of anti-C1q are not
of cross reacting nature any more but still contain a significant
(i.e., detectable) fraction that is not only targeting A08 but
also cross-reacting with EBNA-1. Vice versa, most antibodies
targeting full EBNA-1 are not targeting EBNA348 (34) and thus
have no obvious potential to cross-react with C1q because of
a lack of sequence homology in these parts of the molecule.
Based on these considerations we would expect that only a
minor fraction of all anti-EBNA-1 IgG in an adult patient
have the potential to cross-react with C1q. Taken together, we
think that in patients with advanced SLE there is only a small
fraction of cross-reacting antibodies at the protein level with
the much larger fraction containing unrelated antibodies. In
line with this hypothesis, we could achieve a median inhibition
of 9% of anti-C1q IgG levels when incubating them with
recombinant EBNA-1.
Last, we induced “de novo synthesis” of cross-reacting
antibodies and eventually anti-C1q in animals that have no
intrinsic anti-C1q. By that we confirmed our hypothesis
that anti-C1q in SLE patients might be promoted by an
EBNA-1-derived peptide epitope, in vivo. Interestingly, while
immunization of C1qa−/− mice with the EBNA348 peptide
clearly induced antibodies cross-reacting with A08 of C1q
as well as intact C1q, in C57BL/6N mice antibodies against
A08 could only be detected at very low level in one out
of eight mice. A well conceivable explanation for this is
that the murine C1q in C57BL/6N mice induces tolerance
to the GRRGR sequence-comprising epitope. For this reason
we chose C1q−/− mice that lack intrinsic C1q that would
prevent a healthy individual from raising anti-Cq autoantibodies.
This way we could observe and measure “de-novo synthesis”
of anti-C1q as a consequence of the immunization with
EBNA348, which would not have been possible in wild-
type mice.
Furthermore, the fact that ANA levels at the time of the
anti-C1q response show no significant difference between the
peptide immunized and CFA/IFA controls, neither in wild-
type nor in C1q−/− mice, together with the significantly
higher anti-C1q levels in the C1q−/− EBNA348-immunized
mice, confirm that the anti-A08 and anti-C1q response
is specific.
In summary, we provide evidence that anti-C1q in SLE
patients could arise from an anti-EBNA-1 immune response.
The present observational data in clinical samples as well
as the in vivo findings suggest a putative role of EBV in
the development of SLE, and should be viewed as a step
in understanding the mechanism of pathogen-induced
autoantibodies in SLE. We speculate that, e.g., an EBV
vaccination could dampen the development of cross-reactive
antibodies in individuals genetically predisposed to SLE.
However, EBV vaccines to prevent primary infection or
therapeutic vaccines to reduce the viral load in EBV-associated
malignancies have not yet been licensed. As an alternative
strategy, selective immune-modulators might be able to
suppress the production of cross-reacting autoantibodies
in EBV-infected individuals with genetic predisposition
to autoimmunity.
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